BioSpace News Archive

Good Therapeutics, a privately held company, today announced it has entered into a definitive merger agreement to be acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY).

2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa-9 study to evaluate Abecma (idecabtagene vicleucel) in newly diagnosed multiple myeloma patients who have suboptimal response to transplant.

NEXGEL, Inc. announced that Adam Levy, CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12th – 14th at the Lotte New York Palace Hotel in New York, NY.

Praxis Precision Medicines, Inc. announced the plan to start the PRAX-222 EMBRAVE clinical study for the treatment of pediatric patients with early-seizure-onset SCN2A developmental and epileptic encephalopathy, after the U.S. Food and Drug Administration cleared the Investigational New Drug application for the initial dose cohort.

RELIEF THERAPEUTICS Holding SA announced that Jack Weinstein, Chief Financial Officer and Treasurer, will present a company overview during the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 12-14, 2022.

Zealand Pharma A/S announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® for injection.

NeoGenomics, Inc. announces that its liquid biopsy focused subsidiary Inivata Limited, alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease and recurrence at the European Society for Medical Oncology Congress, taking place September 9th-13th, 2022.

Lytix Biopharma, a Norwegian immuno-oncology company, announces the regulatory approval from European authorities to commence the ATLAS-IT-05 study in three European countries.

TikoMed announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company’s lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus, two strains of Zika virus and Yellow Fever virus assessed by immunofluorescence of viral particles.

Carroucell, the microcarrier supplier for cell culture in bioreactor, announced that it has raised a total of €1.5 million.